Date: 2014-09-29
Type of information: Nomination
Compound: chief operating officer, member of the board of directors
Company: Kymab (UK)
Therapeutic area: Cancer - Oncology - Infectious diseases - Inflammatory diseases - Hematological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 29, 2014, Kymab announced the appointment of Dr Timothy Wells and Lisha Patel to its Board as Non-Executive Directors and Jenny Yip as a Board Observer, effective from 23 September 2014. Dr Richard Davis will stand down as Non-Executive Director.
Dr Timothy Wells, a protein engineer by training, is currently Chief Scientific Officer of the Medicines for Malaria Venture (MMV) in Geneva and was previously Senior Executive Vice President Research at Serono.
- Lisha Patel is Head of Direct Private Investments at the Wellcome Trust and Jenny Yip is Senior Program Investment Officer on the Program Related Investments (PRI) team at the Bill & Melinda Gates Foundation (BMGF).
Kymab also announced two executive promotions. Dr Glenn Friedrich has been promoted to Chief Operating Officer. Dr Friedrich is a founder of the company and previously served as Vice President, then Senior Vice President, of Technology and Research Operations. Dr Friedrich will continue to bring a wealth of experience in R&D management to the Kymab team, now with a broad responsibility for the Company’s operations and finances. Jasper Clube, EPA CPA has been promoted to Senior Vice President Intellectual Property and Chief Patent Counsel. Mr Clube joined Kymab in 2010 and has held senior roles in overseeing all aspects of the Company’s intellectual property strategies and protection.
Financial terms:
Latest news:
Is general: Yes
